Is it possible to control ageing and cancer? Most would say no but Mikhail Blagosklonny, believes otherwise. He has keen interest is the field of ontology and is an author of many publication such as aging hyper function theory and has written about cyclotherapy of cell and chemotherapeutic engineering. Using Rapamycin Mikhail believes cancer can be cured.

His interest in the field of medicine did not start now, he went to Pavlov State Medical University of St. Petersburg and got an MD in internal medicine and further got a PH. D from the same university in Experimental Medicine and Cardiology.

It was in 2009, that Mikhail joined Roswell Park Cancer Institute as a professor of ontology. Previously he was a senior scientist at Ordway Research Institute not before he was working as an associate professor of medicine at New York Medical College. He is well experienced, and his work is on cancer, anti-aging drugs, Biogerontology (Aging Mechanism), and cancer therapies that are targeted and aim at protecting the healthy cells from damage.

Mikhail Blagosklonny has a hypothesis on TOR Signaling potential role in cancer and aging. To extend life, he suggest the use of Rapamycin a drug used in cancer treatment and in longevity research he is seen as the most passionate about the use of Rapamycin. His research is vast and includes ontogenesis, tumor suppression, and cell cycle and also involves cellular and molecular biology to investigations that are clinical.

His interest in finding a cure for cancer makes him best suited to teach at Roswell so as to share his findings and passion with the young minds. Roswell Park Cancer Institute (RPCI) started way back in 1898 and is located in Buffalo, New York, its main focus being cancer research and treatment.

In 2010, Mikhail together with Andrei V.Gudkov went ahead to start Oncotarget a weekly peer-review open access medical journal. Oncotarget is a term covering all molecules, cellular function, and pathways common in cancer and aging, atherosclerosis, lymphocytes, cancer cells, and neurodegeneration. Thus the paper aim is to make results that are scientific rapid and widely available. The success of the Oncotarget provides more avenues for research and cancer cure development, and this gives hope to cancer patients.

Visit this page: gettingstronger.org

Highlights Of The Business Career And Pharmaceutical Management of JeanMarie Guenot


JeanMarie Guenot is an experienced business administrator in the biotechnology and pharmaceutical industries. JeanMarie has served in the private and public sectors for more than 20 years. Presently, she is the president of Amphivera Therapeutics Inc., which is based in San Francisco. In this company, she has rendered her services in different sections, including corporate and commercial development, pharmaceutical R&D, project and alliance management, and business development.

Guenot has extensive expertise in rebuilding firms. Amphivena Therapeutics, Inc. has been creating innovative bifunctional antibody therapies for many years. These therapies are used for hematologic malignances. Through the company, Guenot provides specialized services such as mergers and acquisition, licensing, project management, and commercial planning.

Previously, listed on her personal website, Guenot developed and managed SKS Ocular. It was an ophthalmic firm incubator specializing on dry AMD. In addition, Guonet was Hoffmann-La Roche’s business advisor. She was based in Basel and Shanghai. She also worked for PDL BioPharma as the vice president in charge of corporate and business development.

At the company, her Amphivena bio tells us that Guenot negotiated and headed the Biogen Idec-PDL 50:50 co-commercialization & co-development strategic partnership. It involved the three phase 2 cancer therapies in addition to autoimmune disease drug subjects. She played an instrumental role towards the success of the $800 million deal. Guenot has vast experience and knowledge in managing project, alliance, and portfolio management in the fields of autoimmune diseases, oncology, and cardiovascular diseases.

JeanMarie Guenot studied physical and medicinal chemistry, something she speaks highly of on Facebook. She is skilled in drug design, semi-empirical and quantum mechanical methods, NMR and refinement, X-ray, and protein structure prediction. Guenot graduated with her MBA from the University of Pennsylvania’s Wharton School and a PhD from the University of California. She began her business career at Atlas Venture. In this corporation, JeanMarie built life science firms and run venture capital investments. Guenot started her scientific profession by working as a chief scientist in Preclinical R&D at Hoffman.

Throughout her career, JeanMarie has focused on finding solutions to the challenges faced by people and different organizations. Her expertise in different fields has made her a vibrant professional who works on creating a difference in the world. Currently, Jeanmarie Guenot resides in San Francisco.